Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CRNX |
---|---|---|
09:32 ET | 5055 | 45.98 |
09:34 ET | 400 | 46.07 |
09:36 ET | 700 | 45.98 |
09:39 ET | 5650 | 46.4 |
09:41 ET | 3300 | 46.085 |
09:43 ET | 323 | 46.0101 |
09:45 ET | 1214 | 45.915 |
09:48 ET | 3551 | 45.785 |
09:50 ET | 1600 | 45.65 |
09:52 ET | 350 | 45.75 |
09:54 ET | 400 | 45.815 |
09:56 ET | 1400 | 45.765 |
09:57 ET | 177 | 45.93 |
09:59 ET | 100 | 45.71 |
10:03 ET | 600 | 45.7278 |
10:06 ET | 500 | 45.77 |
10:08 ET | 1652 | 45.565 |
10:12 ET | 1232 | 45.64 |
10:14 ET | 499 | 45.7283 |
10:15 ET | 800 | 45.55 |
10:17 ET | 1121 | 45.6 |
10:19 ET | 1100 | 45.575 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Crinetics Pharmaceuticals Inc | 3.7B | -12.1x | --- |
Biohaven Ltd | 3.3B | -4.4x | --- |
Immunovant Inc | 4.1B | -17.2x | --- |
SpringWorks Therapeutics Inc | 3.1B | -8.1x | --- |
Vitaspring Biomedical Co. Ltd | 3.1B | 3,311.3x | --- |
Nuvalent Inc | 4.3B | -27.4x | --- |
Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its Paltusotine, an investigational, oral somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. It has demonstrated pharmacologic proof-of-concept in a Phase 1 clinical study for CRN04894, an investigational, oral ACTH antagonist, that is in Phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and Cushing's disease. Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.7B |
---|---|
Revenue (TTM) | $2.0M |
Shares Outstanding | 78.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.66 |
EPS | $-3.77 |
Book Value | $7.91 |
P/E Ratio | -12.1x |
Price/Sales (TTM) | 1,872.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -12,571.38% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.